41 results about "Immunologic Competence" patented technology

Improved methods, reagents, and kits for quantitation of HLA-DR and / or CD11b expression on peripheral blood cells are presented. Inclusion of a lysosomotropic amine, such as chloroquine, during staining stabilizes HLA-DR and CD11b expression. Use of a novel anti-CD14 conjugate, anti-CD14-PerCP / CY5.5, permits the ready discrimination of monocytes. The improved methods, reagents, and kits may be used to assess immune competence, and to direct and monitor immunostimulatory therapies in septic patients exhibiting monocyte deactivation.

The invention relates to a method for the preparation of efficient antigen-presenting human γδ T cells, to the γδ T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human γδ T cells process antigens and present antigenic peptides to αβ T cells and induce antigen-specific responses (proliferation and differentiation) in naïve αβ T cells. γδ T cells are easily purified from peripheral blood, acquire “maturation” status (expression of essential adhesion, co-stimulatory and major histocompatibility complex molecules) within 1 day of in vitro culture under stimulation and induce strong primary and secondary T helper cell responses. The γδ T cells may be used in a method of treatment of tumors or chronic or recurrent infectious diseases, in identification of novel tumor or pathogen-derived antigens, and in the diagnosis of the immune competence of a patient.

The invention relates to a method for the preparation of efficient antigen-presenting human γδ T cells, to the γδ T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human γδ T cells process antigens and present antigenic peptides to αβ T cells and induce antigen-specific responses (proliferation and differentiation) in naïve αβ T cells. γδ T cells are easily purified from peripheral blood, acquire “maturation” status (expression of essential adhesion, co-stimulatory and major histocompatibility complex molecules) within 1 day of in vitro culture under stimulation and induce strong primary and secondary T helper cell and cytotoxic T cell responses. The γδ T cells may be used in a method of treatment of tumors or chronic or recurrent infectious diseases, in identification of novel tumor or pathogen-derived antigens, and in the diagnosis of the immune competence of a patient.

The present disclosure relates to a Fusobacterium nucleatum FomA protein vaccine, a preparation method and applications thereof. The preparation method comprises: linking a signal-peptide-sequence-deleted FomA gene linked to a MBP tag to an expression vector, transforming into Escherichia coli, carrying out induced expression, carrying out affinity purification on FomA recombinant protein by usingAmylose Resin High Flow, and carrying out enzyme digestion with a tev enzyme to remove the MBP tag to obtain the Fusobacterium nucleatum FomA protein vaccine. According to the present invention, theFusobacterium nucleatum FomA protein vaccine has good stability, and can effectively improve the immunity of organisms to Fusobacterium nucleatum, improve the survival rate and delay the occurrence and development of colons tumor; and in APCMin / + mice models, the FomA protein vaccine has significant protecting effect on the mice, can be used as a new colon tumor vaccine candidate, and has great application prospects.

The invention relates to a method for the preparation of efficient antigen-presenting human γδ T cells, to the γδ T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human γδ T cells process antigens and present antigenic peptides to αβ T cells and induce antigen-specific responses (proliferation and differentiation) in naïve αβ T cells. γδ T cells are easily purified from peripheral blood, acquire “maturation” status (expression of essential adhesion, co-stimulatory and major histocompatibility complex molecules) within 1 day of in vitro culture under stimulation and induce strong primary and secondary T helper cell and cytotoxic T cell responses. The γδ T cells may be used in a method of treatment of tumors or chronic or recurrent infectious diseases, in identification of novel tumor or pathogen-derived antigens, and in the diagnosis of the immune competence of a patient.

The invention discloses the preparation and application of an antimicrobial peptide fusion cytokine CAMPILs co-expression biological preparation. The antimicrobial peptide fusion cytokine CAMPILs provided by the present invention is as follows A1), A2) or A3): A1) the amino acid sequence is the protein of sequence 1 in the sequence listing; A2) the amino acid sequence shown in sequence 1 in the sequence listing is passed through a or several amino acid residue substitutions and / or deletions and / or additions and proteins with the same function; A3) A fusion protein obtained by linking tags at the N-terminal or / and C-terminal of A1) or A2). Experiments have proved that CAMPILs of the present invention can promote the proliferation of lymphocytes, red blood cells and white blood cells, inhibit the growth of pathogenic microorganisms, promote the secretion of non-specific antibodies (IgG, IgG1, IgG2a) and disease-specific antibodies, and improve the immunity and survival of animals. Rate.

The invention discloses an active polypeptide composition and its application in animal vaccines, including Lys-His-Gly-NH 2 And Salpichrolide O is specially used to improve the immunity of animals such as chickens, ducks, rabbits, pigs, sheep, dogs, cattle, deer and other livestock, poultry and various economic animals, and can improve the immune effect of vaccines. Since the active polypeptide is a pure natural substance existing in the animal body, with a small molecular weight, it is non-toxic when used alone or together with the vaccine, and does not produce antibodies against the active polypeptide. It improves the body's immunity by improving the host's own immune response ability, which is very safe. ,reliable. The chemical synthesis of active peptides is convenient and low-cost, and the use of pharmaceutical-grade active peptides is safer and more reliable. Salpichrolide O is also a pure natural substance with small molecular weight. It is non-toxic when used alone or with vaccines. It can further improve the host's own immune response ability and further improve the body's immunity when used in conjunction with active peptides.

The invention relates to a novel lactobacillus strain and a novel composition which contains an unknown strain which can be used for enhancing the anti-allergic capability. The composition can exist in the form of food or medicinal composition. A method for screening and testing the lactobacillus strain composition for enhancing the Th1 immunological competence and regulate overreacting Th2 immunologic reaction caused by allergy is also disclosed.

The invention relates to bursa of Fabricius heptapeptide with immune regulation effect and application thereof in immunity (in improving the immune capability of animals, improving the immune effect of vaccines and affecting the activity of tumor cells), and belongs to the field of immunology. The molecular weight of the separated heptapeptide is 722.240, the amino acid sequence is EPASGMM, and the heptapeptide has a simple structure, no toxic or side effect and extremely weak immunogenic property. The heptapeptide can be separated and extracted from bursa of Fabricius, also can be chemically synthesized, has low cost, and can be massively produced. The bursa of Fabricius heptapeptide has induction effect on the production of antibody and subtype thereof, and meanwhile can regulate the production of cell factors, partition of T lymphocytes and proliferation of spleen cells, and promote the immune reaction of the cells. The bursa of Fabricius heptapeptide is an immune regulation factoron functions, has wide application prospect on the aspects of immune regulation, immune therapy and the like, and can be applied in the fields of basic immune research, clinical application research and the like.

The invention discloses engineered yeast of a fish natural killer cell enhancer and an application thereof. The puffer fish NKEF engineered yeast is named as saccharomyces cerevisiae INVSC1-pYES2-NKEFwith the preservation number of CGMCC1847. The engineered yeast is obtained by inserting the puffer fish NKEF gene into the place between EcoRI and XhoI restriction enzyme cutting sites of a pYES2 carrier to construct a recombinant plasmid and then introducing the recombinant plasmid into the expression host saccharomyces cerevisiae. The engineered yeast is cultivated under the condition of 30 oC, induced by 2% galactose, and the expression of NKEF recombinant protein can reach more than 20%. The anti-disease application of the above-mentioned engineered yeast in aquatic animal breeding is also disclosed, and the effect of improving the anti-infective capability and autoimmune capability of aquaculture animals can be achieved.

The invention discloses preparation and application of a fusion bovine antibacterial peptide (FBAP) recombinant yeast preparation. The invention provides four kinds of bovine antibacterial peptides; amino acid sequences of the four kinds of bovine antibacterial peptides are 1-12 sites of a sequence 1, 21-32 sites of the sequence 1, 41-55 sites of the sequence 1 and 63-75 sites of the sequence 1 respectively. Proved by experiments, the FBAP provided by the invention can promote proliferation of lymphocytes, erythrocytes and leukocytes, inhibits growth of pathogenic microorganisms, promotes secretion of non-specific antibodies (IgG, IgG1 and IgG2a) and disease-specific antibodies, improves the immunity of animals and increases the survival rate of the animals.